Randomized trial reanalysis demonstrates superior overall outcomes for voriconazole over amphotericin B in invasive aspergillosis, highlighting the benefit of comprehensive outcome ranking.
Efficacy of antifungal therapy in invasive aspergillosis relies primarily on mortality, overlooking critical measures of treatment response. We used the Mycoses Study Group Education & Research Consortium (MSG) Desirability of Outcome Ranking (DOOR) framework to assess efficacy of antifungal therapies by integrating mortality, treatment failure, and severe adverse events. Voriconazole achieved better overall outcomes than amphotericin B using the DOOR approach.
No takes yet. Share an insight, caveat, or question.
Zuniga-Moya et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: